Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri.
McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
Cancer Res Commun. 2023 Nov 15;3(11):2312-2330. doi: 10.1158/2767-9764.CRC-23-0140.
The malignant Hodgkin and Reed Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) are scarce in affected lymph nodes, creating a challenge to detect driver somatic mutations. As an alternative to cell purification techniques, we hypothesized that ultra-deep exome sequencing would allow genomic study of HRS cells, thereby streamlining analysis and avoiding technical pitfalls. To test this, 31 cHL tumor/normal pairs were exome sequenced to approximately 1,000× median depth of coverage. An orthogonal error-corrected sequencing approach verified >95% of the discovered mutations. We identified mutations in genes novel to cHL including: CDH5 and PCDH7, novel stop gain mutations in IL4R, and a novel pattern of recurrent mutations in pathways regulating Hippo signaling. As a further application of our exome sequencing, we attempted to identify expressed somatic single-nucleotide variants (SNV) in single-nuclei RNA sequencing (snRNA-seq) data generated from a patient in our cohort. Our snRNA analysis identified a clear cluster of cells containing a somatic SNV identified in our deep exome data. This cluster has differentially expressed genes that are consistent with genes known to be dysregulated in HRS cells (e.g., PIM1 and PIM3). The cluster also contains cells with an expanded B-cell clonotype further supporting a malignant phenotype. This study provides proof-of-principle that ultra-deep exome sequencing can be utilized to identify recurrent mutations in HRS cells and demonstrates the feasibility of snRNA-seq in the context of cHL. These studies provide the foundation for the further analysis of genomic variants in large cohorts of patients with cHL.
Our data demonstrate the utility of ultra-deep exome sequencing in uncovering somatic variants in Hodgkin lymphoma, creating new opportunities to define the genes that are recurrently mutated in this disease. We also show for the first time the successful application of snRNA-seq in Hodgkin lymphoma and describe the expression profile of a putative cluster of HRS cells in a single patient.
经典霍奇金淋巴瘤(cHL)中的恶性霍奇金和里德斯特恩伯格(HRS)细胞在受影响的淋巴结中很少见,这给检测驱动性体细胞突变带来了挑战。作为细胞纯化技术的替代方法,我们假设超深度外显子组测序将允许对 HRS 细胞进行基因组研究,从而简化分析并避免技术陷阱。为了验证这一点,对 31 例 cHL 肿瘤/正常对进行了外显子组测序,测序深度约为中位数的 1000 倍。一种正交的纠错测序方法验证了超过 95%的已发现突变。我们在 cHL 中发现了包括 CDH5 和 PCDH7 在内的新基因的突变,IL4R 中的新型无义获得突变,以及 Hippo 信号通路调控中复发性突变的新模式。作为我们外显子组测序的进一步应用,我们试图在我们队列中的一位患者的单细胞 RNA 测序(snRNA-seq)数据中识别表达的体细胞单核苷酸变异(SNV)。我们的 snRNA 分析鉴定了一个明确的细胞簇,其中包含我们在深度外显子数据中鉴定的体细胞 SNV。该簇具有差异表达的基因,这些基因与已知在 HRS 细胞中失调的基因(例如,PIM1 和 PIM3)一致。该簇还包含具有扩展 B 细胞克隆型的细胞,进一步支持恶性表型。这项研究提供了一个原理证明,即超深度外显子组测序可用于鉴定 HRS 细胞中的反复突变,并证明了 snRNA-seq 在 cHL 中的可行性。这些研究为进一步分析大量 cHL 患者的基因组变异奠定了基础。
我们的数据表明,超深度外显子组测序在揭示霍奇金淋巴瘤中的体细胞变异方面具有实用性,为定义该疾病中反复突变的基因提供了新的机会。我们还首次展示了 snRNA-seq 在霍奇金淋巴瘤中的成功应用,并描述了单个患者中推定的 HRS 细胞簇的表达谱。